case ID,acute/sustained,daily dosage,total dosage,dosage value,dosage units,dosage times per day,dosage duration,dosage comment,intervention class,intervention,dose dependence,sample group size,prophylactic / therapeutic,outcome,outcome direction,measure description,outcome group size,author conclusion,conclusion method,References,NCT Number,Title,Gender,Age Groups,Age Description,Phases,URL,intervention:Specific,intervention:Variation
NCT02626104-2,sustained,,,,,,,,control,100 mg of placebo - maltodextrin twice a day orally for the whole period of antibiotic therapy.,no,78,prophylactic,Occurence of antibiotic-associated diarrhoea. [ Time Frame: Up to 24 days after initiation of antibiotic treatment. ],negative,participants,7,,,https://www.embase.com/a/#/search/results?subaction=viewrecord&rid=1&page=1&id=L622343677,NCT02626104,Bovine Lactoferrin and Antibiotic-associated Diarrhoea.,All,"Child, Adult","1 Year to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02626104,,
NCT00958308-1,sustained,,,1,capsule,,,50 billion CFU,probiotic,"BIO-K+ CL-1285, one capsule + one capsule placebo",yes,85,prophylactic,CDAD occurrence,negative,participants,8,,,https://journals.lww.com/ajg/Abstract/2010/07000/Dose_Response_Efficacy_of_a_Proprietary_Probiotic.30.aspx,NCT00958308,Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection,All,"Adult, Older Adult","50 Years to 70 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00958308,,Lactobacillus acidophilus
NCT00958308-3,sustained,,,2,capsule,,,50 billion CFU,probiotic,"BIO-K+ CL-1285, two capsules",yes,86,prophylactic,CDAD occurrence,negative,participants,1,,,https://journals.lww.com/ajg/Abstract/2010/07000/Dose_Response_Efficacy_of_a_Proprietary_Probiotic.30.aspx,NCT00958308,Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection,All,"Adult, Older Adult","50 Years to 70 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00958308,,Lactobacillus acidophilus
NCT02626104-1,sustained,200,,100,mg,BID,,for antiobiotic duration,other,bovine lactoferrin ,no,78,prophylactic,Occurence of antibiotic-associated diarrhoea. [ Time Frame: Up to 24 days after initiation of antibiotic treatment. ],negative,participants,16,inferior,,https://www.embase.com/a/#/search/results?subaction=viewrecord&rid=1&page=1&id=L622343677,NCT02626104,Bovine Lactoferrin and Antibiotic-associated Diarrhoea.,All,"Child, Adult","1 Year to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02626104,,
NCT01983683-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,290,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,81 (76.1 to 85.1)   ,Non-Inferiority,Wilson's score method,x,NCT01983683,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01983683,Cadazolid,
NCT01983683-3,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,290,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,63.4 (57.8 to 68.8),Superiority,Wilson's score method,x,NCT01983683,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01983683,Cadazolid,
NCT01987895-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,Cadazolid,
NCT01987895-3,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,Cadazolid,
NCT01222702-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,Cadazolid,
NCT01222702-4,acute,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,Cadazolid,
NCT01222702-7,acute,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,Cadazolid,
NCT01222702-13,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,Cadazolid,
NCT01222702-16,sustained,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,Cadazolid,
NCT01222702-19,sustained,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,Cadazolid,
NCT01085591-1,acute,250,2500,125,mg,BID,10,,antibiotic,"CB-183,315",yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,61,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,"CB-183,315;surotomycin",
NCT01085591-3,acute,500,5000,250,mg,BID,10,,antibiotic,"CB-183,315",yes,67,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,58,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,"CB-183,315;surotomycin",
NCT01085591-7,sustained,250,2500,125,mg,BID,10,,antibiotic,"CB-183,315",yes,61,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,negative,participants,17,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,"CB-183,315;surotomycin",
NCT01085591-10,sustained,500,5000,250,mg,BID,10,,antibiotic,"CB-183,315",yes,58,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,negative,participants,10,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,"CB-183,315;surotomycin",
NCT02254967-1,acute,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,extended-pulsed fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,,fidaxomicin;Tiacumicins B
NCT02254967-3,sustained,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,extended-pulsed fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,,fidaxomicin;Tiacumicins B
NCT01704937-1,sustained,,,,,,,,FMT,"Fecal microbiota transplant (""stool transplant"") from healthy, unrelated donor via colonoscopy",no,10,therapeutic,Efficacy is defined as resolution of C. Difficile signs and symptoms off antibiotics for C. difficile,positive,participants,8,,,https://pubmed.ncbi.nlm.nih.gov/24762631/,NCT01704937,Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum,All,"Child, Adult, Older Adult","7 Years to 90 Years Â (Child, Adult, Older Adult)",Phase 1,https://ClinicalTrials.gov/show/NCT01704937,,FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates
NCT01704937-2,sustained,,,,,,,,FMT,"Fecal microbiota transplant (""stool transplant"") from healthy, unrelated donor via NGT",no,10,therapeutic,Efficacy is defined as resolution of C. Difficile signs and symptoms off antibiotics for C. difficile,positive,participants,6,,,https://pubmed.ncbi.nlm.nih.gov/24762631/,NCT01704937,Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum,All,"Child, Adult, Older Adult","7 Years to 90 Years Â (Child, Adult, Older Adult)",Phase 1,https://ClinicalTrials.gov/show/NCT01704937,,FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates
NCT02465463-1,sustained,250,250,250,mL,QD,1,,FMT,Fecal microbiota transplant (FMT): 250 mL of donor stool will be infused into the colon by flexible sigmoidoscopy,no,4,therapeutic,Clinical Remission Rates [ Time Frame: Post-Intervention (Week 12) ],positive,participants,3,,,x,NCT02465463,Early FMT for C.Difficile,All,"Adult, Older Adult","18 Years to 79 Years Â (Adult, Older Adult)",Phase 1|Phase 2,https://ClinicalTrials.gov/show/NCT02465463,,FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates
NCT02254811-2,sustained,,,,,,,,FMT,Fecal microbiota transplant delivered by colonoscopy,no,59,therapeutic,Proportion of patients without recurrent CDI [ Time Frame: 12 weeks after treatment ],positive,participants,50,non-inferiority,"(difference, 0%; 1-sided 95% CI, -6.1% to infinity; P < .001),",https://pubmed.ncbi.nlm.nih.gov/29183074/,NCT02254811,FMT Delivered by Capsule Versus Colonoscopy for Recurrent C. Diff,All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2|Phase 3,https://ClinicalTrials.gov/show/NCT02254811,,FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates
NCT02254811-1,sustained,,,,,,,,FMT,Fecal microbiota transplant is delivered by oral capsules,no,57,therapeutic,Proportion of patients without recurrent CDI [ Time Frame: 12 weeks after treatment ],positive,participants,51,non-inferiority,"(difference, 0%; 1-sided 95% CI, -6.1% to infinity; P < .001),",https://pubmed.ncbi.nlm.nih.gov/29183074/,NCT02254811,FMT Delivered by Capsule Versus Colonoscopy for Recurrent C. Diff,All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2|Phase 3,https://ClinicalTrials.gov/show/NCT02254811,,FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates
NCT02148601-1,sustained,,,,,,,,FMT,Fecal Microbiota Transplantation,no,20,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,18,superior,(P < 0.0001).,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,,FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates
NCT03106844-1,sustained,,,,,,,,FMT,Fecal Microbiota Transplantation,no,49,therapeutic,Number of Participants With FMT Failure [ Time Frame: 8 weeks ] - recurrence of c diff,negative,participants,4,,,x,NCT03106844,The ICON Study: Outcomes After FMT for Patients With IBD and CDI,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 1|Phase 2,https://ClinicalTrials.gov/show/NCT03106844,,FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates
NCT01087892-1,acute,200,1400,100,g,BID,7,7 days + duration of antibiotics,probiotic,fermented milk preparation of L. casei DN114001 (108 colony-forming units (cfu)/mL) as well as two regular yoghurt cultures L. delbrueckii subspecies bulgaricus and S. thermophilus (106 cfu/mL),no,549,prophylactic,incidence and duration of Clostridium difficile toxin [ Time Frame: regular intervals for 28 days from entry to trial ],negative,participants,8,not superior,,https://www.journalofhospitalinfection.com/article/S0195-6701(20)30042-6/fulltext,NCT01087892,Probiotics in Preventing Antibiotic Associated Diarrhoea Including Clostridium Difficile Infection,All,"Adult, Older Adult","55 Years and older Â (Adult, Older Adult)",Not Applicable,https://ClinicalTrials.gov/show/NCT01087892,,
NCT01591863-1,acute,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,Fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Clinical Response. (day 10),positive,Percentage of participants,92.1 (83.5 to 100),,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,fidaxomicin;Tiacumicins B,
NCT01591863-2,sustained,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,Fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Sustained Clinical Response. (day 28),positive,Percentage of participants,65.8 (50.7 to 80.9),,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,fidaxomicin;Tiacumicins B,
NCT02179658-1,acute,400,4000,200,mg,BID,10,,antibiotic,Fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,fidaxomicin;Tiacumicins B,
NCT02179658-3,sustained,400,4000,200,mg,BID,10,,antibiotic,Fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,fidaxomicin;Tiacumicins B,
NCT02743234-3,acute,400,4000,200,mg,BID,10,,antibiotic,Fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,fidaxomicin;Tiacumicins B,
NCT02743234-9,sustained,400,4000,200,mg,BID,10,,antibiotic,Fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",negative,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,fidaxomicin;Tiacumicins B,
NCT02784002-1,sustained,400,4000,200,mg,BID,10,,antibiotic,Fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,6,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,fidaxomicin;Tiacumicins B,
NCT02218372-1,acute,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,fidaxomicin;Tiacumicins B,
NCT02218372-3,sustained,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,fidaxomicin;Tiacumicins B,
NCT01691248-1,sustained,200,16000,200,mg,QD,40,up to 40 days,antibiotic,Fidaxomicin,no,301,prophylactic,Percentage of Participants With Occurrence of CDAD From Start of Study Treatment up to 30 Days Post-treatment Follow-up. [ Time Frame: Up to 30 days post-treatment ],negative,Percentage of participants,28.6 (23.5 to 33.7),not superior,1-sided Wald test for a difference in proportions using an unpooled estimate of variance.,x,NCT01691248,Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01691248,fidaxomicin;Tiacumicins B,
NCT02437591-1,acute,400,4000,200,mg,BID,10,,antibiotic,Fidaxomicin,no,25,therapeutic,CDI clinical response [ Time Frame: Day 12 ],positive,participants,20,,,https://astellasclinicalstudyresults.com/study.aspx?ID=227,NCT02437591,Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02437591,fidaxomicin;Tiacumicins B,
NCT00314951-2,acute,400,4000,200,mg,BID,10,,antibiotic,Fidaxomicin,no,289,therapeutic,Cure Rate at End of Therapy [ Time Frame: Study day 10 (+/- 2 days) ],positive,Percentage of participants,88.2 (84.0 to 91.5),non-inferior,"H0: C(fidaxomicin) - C(Vancomycin) <= -10% Power calculation is based on cure rate of 85% in both treatment groups, non-inferiority margin of 10%, 2.5% (1-sided) type I error rate with approximately 90% power gives a total of 530 subjects.",x,NCT00314951,Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018),All,"Child, Adult, Older Adult","16 Years and older Â (Child, Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00314951,fidaxomicin;Tiacumicins B,
NCT00314951-4,sustained,400,4000,200,mg,BID,10,,antibiotic,Fidaxomicin,no,255,therapeutic,Recurrence [ Time Frame: Study days 11-40 ],negative,Percentage of participants,15.7,superior,Chi-squared,x,NCT00314951,Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018),All,"Child, Adult, Older Adult","16 Years and older Â (Child, Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00314951,fidaxomicin;Tiacumicins B,
NCT01818141-1,acute,400,4000,200,mg,BID,10,200 mg BID for 10 days,antibiotic,Fidaxomicin 200mg by mouth every 12 hours for 10 days,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,fidaxomicin;Tiacumicins B,
NCT01818141-3,acute,400,4000,200,mg,BID,10,200mg BID for 10 days,antibiotic,Fidaxomicin 200mg by mouth every 12 hours for 10 days,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,fidaxomicin;Tiacumicins B,
NCT02743234-1,acute,,,,,,,,FMT,FMT following 4-10 days vancomycin 125mgx4 daily,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,17,superior,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,,FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates
NCT02743234-7,sustained,,,,,,,,FMT,FMT following 4-10 days vancomycin 125mgx4 daily,no,24,therapeutic,"initially cured, then relapsed",negative,participants,2,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,,FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates
NCT01398969-1,sustained,,,,,,,,FMT,Fresh Human Biotherapy,no,111,therapeutic,To determine the cure rate without recurrence of CDI at 13 weeks from the last HBT. [ Time Frame: 13 Weeks post HBT ],positive,participants,78,,"(difference, 4.7% [95% CI, -5.2% to ∞]; P < .001 for noninferiority)",https://pubmed.ncbi.nlm.nih.gov/26757463/,NCT01398969,Multi-Centre Trial of Fresh vs. Frozen-and-Thawed HBT(Fecal Transplant)for Recurrent CDI,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01398969,,FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates
NCT01398969-2,sustained,,,,,,,,FMT,Frozen-and-Thawed Human Biotherapy,no,108,therapeutic,To determine the cure rate without recurrence of CDI at 13 weeks from the last HBT. [ Time Frame: 13 Weeks post HBT ],positive,participants,81,non-inferior,,https://pubmed.ncbi.nlm.nih.gov/26757463/,NCT01398969,Multi-Centre Trial of Fresh vs. Frozen-and-Thawed HBT(Fecal Transplant)for Recurrent CDI,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01398969,,FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates
NCT02951702-2,sustained,,,,,,,,control,historical control,no,34,prophylactic,Clostridium Difficile Infection Occurrence [ Time Frame: Within 4 weeks from the completion of antibiotic treatment ],negative,participants,2,,,x,NCT02951702,Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics,All,Older Adult,65 Years and older Â (Older Adult),Phase 4,https://ClinicalTrials.gov/show/NCT02951702,,
NCT02951702-4,sustained,,,,,,,,control,historical control,no,34,prophylactic,Time to Clostridium Difficile Infection Occurence,positive,days,2,,,x,NCT02951702,Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics,All,Older Adult,65 Years and older Â (Older Adult),Phase 4,https://ClinicalTrials.gov/show/NCT02951702,,
NCT00328263-1,sustained,1,5,1,bottle,QD,5,"5 + duration of antibiotics, 50 billion CFU/bottle",probiotic,Lactobacillus acidophilus CL1285 and Lactobacillus casei,no,0,prophylactic,Positive Results for Clostridium Difficile (C. Difficile) Toxin A or B in Antibiotic Associated Diarrhea Patients.,negative,participants,0,inconclusive,,x,NCT00328263,Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00328263,,Lactobacillus acidophilus
NCT02865616-1,sustained,,,,,,,staggered dosing depending on outcome,probiotic,MET-2,no,19,therapeutic,absence of C difficile infection recurrence at day 40,positive,participants,18,,,https://pubmed.ncbi.nlm.nih.gov/33631102/,NCT02865616,MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 1,https://ClinicalTrials.gov/show/NCT02865616,,
NCT00182429-1,sustained,1500,15000,500,mg,TID,10,,antibiotic,Metronidazole,no,20,therapeutic,Resolution of symptoms in each treatment arm (in days) up to 40 days (measured using daily stool and symptom diary).,positive,participants,4,,,https://academic.oup.com/cid/article/43/5/547/503445,NCT00182429,Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment,All,"Child, Adult, Older Adult","14 Years and older Â (Child, Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00182429,metronidazole,
NCT00196794-3,acute,1500,15000,375,mg,QID,10,,antibiotic,Metronidazole,no,135,therapeutic,Resolution of diarrhea,positive,Percentage of participants,73.3,,,https://pubmed.ncbi.nlm.nih.gov/24799326/,NCT00196794,A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00196794,metronidazole,
NCT00196794-9,sustained,1500,15000,375,mg,QID,10,,antibiotic,Metronidazole,no,106,therapeutic,Recurrence rate,negative,Percentage of participants,18.9,,,https://pubmed.ncbi.nlm.nih.gov/24799326/,NCT00196794,A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00196794,metronidazole,
NCT00106509-3,acute,1500,15000,375,mg,QID,10,,antibiotic,Metronidazole,no,143,therapeutic,Resolution of diarrhea,positive,Percentage of participants,72,,,https://pubmed.ncbi.nlm.nih.gov/24799326/,NCT00106509,A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00106509,metronidazole,
NCT00106509-9,sustained,1500,15000,375,mg,QID,10,,antibiotic,Metronidazole,no,107,therapeutic,Recurrence rate,negative,Percentage of participants,27.1,,,https://pubmed.ncbi.nlm.nih.gov/24799326/,NCT00106509,A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00106509,metronidazole,
NCT01241552-1,sustained,10,10,10,mg/kg,QD,1,,antibody,MK-3415 + Standard of Care,no,232,therapeutic,Percentage of Participants With CDI Recurrence,negative,Percentage of participants,25.9,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,,CDA1
NCT01513239-1,sustained,10,10,10,mg/kg,QD,1,,antibody,MK-6072 + Standard of Care,no,390,therapeutic,Percentage of Participants With CDI Recurrence,negative,Percentage of participants,14.9,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,,MDX1388
NCT01241552-6,sustained,10,10,10,mg/kg,QD,1,,antibody,MK-6072 + Standard of Care,no,386,therapeutic,Percentage of Participants With CDI Recurrence,negative,Percentage of participants,17.4,superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,,MDX1388
NCT00304356-1,sustained,1000,,500,mg,BID,,,other,Nitazoxanide,no,27,therapeutic,Nitazoxanide [ Time Frame: 30 days ] - stopping of diarrhea,positive,participants,27,,,x,NCT00304356,Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00304356,Nitazoxanide,
NCT02465463-2,sustained,,,,,,,,control,no intervention,no,4,therapeutic,Clinical Remission Rates [ Time Frame: Post-Intervention (Week 12) ],positive,participants,2,,,x,NCT02465463,Early FMT for C.Difficile,All,"Adult, Older Adult","18 Years to 79 Years Â (Adult, Older Adult)",Phase 1|Phase 2,https://ClinicalTrials.gov/show/NCT02465463,,
NCT00350298-2,acute,,,,,,,,control,normal saline,no,99,therapeutic,Time to Resolution of Initial CDAD Episode [ Time Frame: Day 0 to Day 84 ],positive,median days,3,,,x,NCT00350298,Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00350298,,
NCT00350298-4,sustained,,,,,,,,control,normal saline,no,99,therapeutic,Number of Participants With Recurrence of Clostridium Difficile Associated Disease (CDAD) [ Time Frame: Day 0 to Day 84 ],negative,participants,25,,,x,NCT00350298,Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00350298,,
NCT00097422-1,acute,100,1000,50,mg,BID,10,50 mg,antibiotic,OPT-80,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,fidaxomicin;Tiacumicins B,
NCT00097422-3,acute,200,2000,100,mg,BID,10,100 mg,antibiotic,OPT-80,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,fidaxomicin;Tiacumicins B,
NCT00097422-5,acute,400,4000,200,mg,BID,10,200 mg,antibiotic,OPT-80,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,fidaxomicin;Tiacumicins B,
NCT00097422-7,sustained,100,1000,50,mg,BID,10,50 mg,antibiotic,OPT-80,yes,10,therapeutic,Recurrence Rate.,negative,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,fidaxomicin;Tiacumicins B,
NCT00097422-9,sustained,200,2000,100,mg,BID,10,100 mg,antibiotic,OPT-80,yes,12,therapeutic,Recurrence Rate.,negative,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,fidaxomicin;Tiacumicins B,
NCT00097422-11,sustained,400,4000,200,mg,BID,10,200 mg,antibiotic,OPT-80,yes,15,therapeutic,Recurrence Rate.,negative,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,fidaxomicin;Tiacumicins B,
NCT03110133-1,sustained,,,,,,,,probiotic,Oral Full-Spectrum MicrobiotaTM (CP101),no,102,therapeutic,"Proportion of patients with no recurrence of symptomatic, laboratory confirmed C. difficile infection [ Time Frame: Week 8 ]",positive,participants,76,superior,"relative risk reduction (RRR) 21%;74.5%(76/102) vs. 61.5%(59/96),p¼0.0488",https://journals.sagepub.com/doi/pdf/10.1177/2050640620968709,NCT03110133,"Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT03110133,,
NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,Oral Vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,59,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,vancomycin,
NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,Oral Vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,negative,participants,21,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,vancomycin,
NCT02951702-1,sustained,125,,125,mg,QD,,unspecified duration,antibiotic,oral vancomycin 125 mg daily,no,17,prophylactic,Clostridium Difficile Infection Occurrence [ Time Frame: Within 4 weeks from the completion of antibiotic treatment ],negative,participants,0,,,x,NCT02951702,Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics,All,Older Adult,65 Years and older Â (Older Adult),Phase 4,https://ClinicalTrials.gov/show/NCT02951702,vancomycin,
NCT02951702-3,sustained,125,,125,mg,QD,,unspecified duration,antibiotic,oral vancomycin 125 mg daily,no,17,prophylactic,Time to Clostridium Difficile Infection Occurence,positive,days,0,,,x,NCT02951702,Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics,All,Older Adult,65 Years and older Â (Older Adult),Phase 4,https://ClinicalTrials.gov/show/NCT02951702,vancomycin,
NCT01914731-1,acute,,,,,,,,FMT,"Oral, Capsulized, Frozen Fecal Microbiota Transplantation",no,20,therapeutic,clinical resolution of diarrhea after the first administration of FMT,positive,participants,14,success,95% CI,https://doi.org/10.1001/jama.2014.13875,NCT01914731,Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum,All,"Child, Adult, Older Adult","7 Years to 90 Years Â (Child, Adult, Older Adult)",Phase 1,https://ClinicalTrials.gov/show/NCT01914731,,FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates
NCT01914731-2,acute,,,,,,,,FMT,"Oral, Capsulized, Frozen Fecal Microbiota Transplantation",no,6,therapeutic,resolution of diarrhea after the second treatment,positive,participants,5,success,95% CI,https://doi.org/10.1001/jama.2014.13875,NCT01914731,Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum,All,"Child, Adult, Older Adult","7 Years to 90 Years Â (Child, Adult, Older Adult)",Phase 1,https://ClinicalTrials.gov/show/NCT01914731,,FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates
NCT01914731-3,sustained,,,,,,,,FMT,"Oral, Capsulized, Frozen Fecal Microbiota Transplantation",no,20,therapeutic,rate of diarrhea resolution at 8-weeks,positive,participants,19,success,95% CI,https://doi.org/10.1001/jama.2014.13875,NCT01914731,Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum,All,"Child, Adult, Older Adult","7 Years to 90 Years Â (Child, Adult, Older Adult)",Phase 1,https://ClinicalTrials.gov/show/NCT01914731,,FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates
NCT00468728-2,acute,400,4000,200,mg,BID,10,,antibiotic,PAR-101/OPT-80,no,253,therapeutic,Cure Rate at End of Therapy [ Time Frame: Study day 10 (+/- 2 days) ],positive,Percentage of participants,87.7 (83.1 to 91.2),non-inferior,"H0: C(OPT-80) - C(VAN) <= -10% Power calculation is based on cure rate of 85% in both treatment groups, non-inferiority margin of 10%, 2.5% (1-sided) type I error rate with approximately 90% power gives a total of 530 subjects.",x,NCT00468728,PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Child, Adult, Older Adult","16 Years and older Â (Child, Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00468728,fidaxomicin;Tiacumicins B,
NCT00468728-4,sustained,400,4000,200,mg,BID,10,,antibiotic,PAR-101/OPT-80,no,222,therapeutic,Recurrence [ Time Frame: Study days 11-40 ],negative,Percentage of participants,12.6,superior,Chi-squared,x,NCT00468728,PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Child, Adult, Older Adult","16 Years and older Â (Child, Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00468728,fidaxomicin;Tiacumicins B,
NCT02437487-2,acute,,,,,,,,control,placebo,no,30,therapeutic,Number of Subjects With CDI Recurrence (8 weeks after),negative,participants,16,,,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa387/5817059,NCT02437487,SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02437487,,
NCT02437487-4,sustained,,,,,,,,control,placebo,no,30,therapeutic,Number of Subjects With CDI Recurrence (8 weeks after),negative,participants,16,,,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa387/5817059,NCT02437487,SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02437487,,
NCT01259726-1,sustained,,,,,,,,control,Placebo,yes,43,therapeutic,Number of Participants With Clostridium Difficile Infection (CDI) Recurrence,negative,participants,13,,,x,NCT01259726,Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01259726,,
NCT02299570-5,sustained,,,,,,,,control,placebo,yes,44,therapeutic,"The primary endpoint is to evaluate treatment success, defined as the absence of CDAD without the need for retreatment with C. difficile anti-infective therapy or fecal transplant (FT) at 56 days after administration of the last assigned study enema, of Group A (two enemas of RBX2660) vs. Group B (two enemas of placebo).",positive,participants,19,,,x,NCT02299570,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02299570,,
NCT01691248-2,sustained,,,,,,,,control,Placebo,no,209,prophylactic,Percentage of Participants With Occurrence of CDAD From Start of Study Treatment up to 30 Days Post-treatment Follow-up. [ Time Frame: Up to 30 days post-treatment ],negative,Percentage of participants,30.8 (25.5 to 36.0),,1-sided Wald test for a difference in proportions using an unpooled estimate of variance.,x,NCT01691248,Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01691248,,
NCT00958308-5,sustained,,,,,,,,control,placebo,yes,84,prophylactic,CDAD occurrence,negative,participants,20,,,https://journals.lww.com/ajg/Abstract/2010/07000/Dose_Response_Efficacy_of_a_Proprietary_Probiotic.30.aspx,NCT00958308,Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection,All,"Adult, Older Adult","50 Years to 70 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00958308,,
NCT01680874-2,acute,,,,,,,,control,placebo,no,15,therapeutic,median Duration of diarrhea [ Time Frame: 4 weeks ],,days,1,,,https://pubmed.ncbi.nlm.nih.gov/28961980/,NCT01680874,Probiotics for Clostridium Difficile Infection in Older Adults,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01680874,,
NCT01680874-4,sustained,,,,,,,,control,placebo,no,15,therapeutic,Recurrence of CDI [ Time Frame: 8 weeks ],negative,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/28961980/,NCT01680874,Probiotics for Clostridium Difficile Infection in Older Adults,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01680874,,
NCT01087892-2,acute,,,,,,,,control,placebo,no,577,prophylactic,incidence and duration of Clostridium difficile toxin [ Time Frame: regular intervals for 28 days from entry to trial ],negative,participants,11,,,https://www.journalofhospitalinfection.com/article/S0195-6701(20)30042-6/fulltext,NCT01087892,Probiotics in Preventing Antibiotic Associated Diarrhoea Including Clostridium Difficile Infection,All,"Adult, Older Adult","55 Years and older Â (Adult, Older Adult)",Not Applicable,https://ClinicalTrials.gov/show/NCT01087892,,
NCT03110133-2,sustained,,,,,,,,control,placebo,no,96,therapeutic,"Proportion of patients with no recurrence of symptomatic, laboratory confirmed C. difficile infection [ Time Frame: Week 8 ]",positive,participants,59,,,https://journals.sagepub.com/doi/pdf/10.1177/2050640620968709,NCT03110133,"Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT03110133,,
NCT01295918-2,sustained,,,,,,,,control,placebo,no,48,prophylactic,To assess if the probiotic L. reuteri is effective in preventing AAD in children [ Time Frame: 2 years ],positive,participants,47,,"The incidence of diarrhoea (defined as at least 3 loose or watery stools per day in a 48-hour period that occurred during or up to 21 days after cessation of antibiotic treatment) was unexpectedly low in both groups - L. reuteri (n=1) versus placebo (n=1): 2,04 vs. 2,1 per 100 (p>0,05, risk ratio 1,02, 95% CI 0,7-1,4).",http://www.journal-imab-bg.org/issues-2015/issue4/vol21issue4p895-900.html,NCT01295918,Probiotic Lactobacillus Reuteri to Prevent Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children,All,"Child, Adult","3 Years to 18 Years Â (Child, Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01295918,,
NCT01670149-2,sustained,,,,,,,,control,placebo,no,61,prophylactic,Difference in % relapse between Rifaximin and placebo at 12 weeks [ Time Frame: 12 weeks ],negative,participants,18,,,https://gut.bmj.com/content/66/Suppl_2/A150.1,NCT01670149,Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01670149,,
NCT00973908-1,acute,,,,,,,,control,Placebo,no,117,prophylactic,Development of Clostridium difficile associated diarrhoea [ Time Frame: 28 days post last antibiotic dose ],negative,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/23618760/,NCT00973908,Probiotics for the Prevention of Antibiotics Associated Diarrhoea and Clostridium Difficile Associated Diarrhoea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2|Phase 3,https://ClinicalTrials.gov/show/NCT00973908,,
NCT02563106-2,sustained,,,,,,,,control,Placebo,no,206,prophylactic,Percentage of Patients With Clostridium Difficile Infection at 4- Weeks of Follow-up.,negative,participants,7,,,x,NCT02563106,A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI,All,"Adult, Older Adult","50 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02563106,,
NCT00328263-2,sustained,,,,,,,,control,placebo,no,0,prophylactic,Positive Results for Clostridium Difficile (C. Difficile) Toxin A or B in Antibiotic Associated Diarrhea Patients.,negative,participants,0,inconclusive,,x,NCT00328263,Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00328263,,
NCT01513239-6,sustained,,,,,,,,control,Placebo + Standard of Care,no,378,therapeutic,Percentage of Participants With CDI Recurrence,negative,Percentage of participants,25.7,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,,vancomycin;vancomycin + metronidazole;metronidazole
NCT01241552-12,sustained,,,,,,,,antibiotic,Placebo + Standard of Care,no,395,therapeutic,Percentage of Participants With CDI Recurrence,negative,Percentage of participants,27.6,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,,vancomycin;vancomycin + metronidazole;metronidazole
NCT01680874-1,acute,,,1,capsule,QD,28,,probiotic,"probiotic combination which will consist of equal amounts of Lactobacillus acidophilus NCFM® (ATCC 700396), Lactobacillus paracasei Lpc-37 (ATCC SD5275), Bifidobacterium lactis Bi-07 (ATCC SC5220), and Bifidobacterium lactis Bl-04 (ATCC SD5219)",no,16,therapeutic,median Duration of diarrhea [ Time Frame: 4 weeks ],,days,0,,,https://pubmed.ncbi.nlm.nih.gov/28961980/,NCT01680874,Probiotics for Clostridium Difficile Infection in Older Adults,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01680874,,consortium of probiotics including five Lactobacilli strains and two Bifidobacterium strains
NCT01680874-3,sustained,,,1,capsule,QD,28,,probiotic,"probiotic combination which will consist of equal amounts of Lactobacillus acidophilus NCFM® (ATCC 700396), Lactobacillus paracasei Lpc-37 (ATCC SD5275), Bifidobacterium lactis Bi-07 (ATCC SC5220), and Bifidobacterium lactis Bl-04 (ATCC SD5219)",no,16,therapeutic,Recurrence of CDI [ Time Frame: 8 weeks ],negative,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/28961980/,NCT01680874,Probiotics for Clostridium Difficile Infection in Older Adults,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01680874,,consortium of probiotics including five Lactobacilli strains and two Bifidobacterium strains
NCT00973908-2,acute,2,14,1,sachet,BID,7,7 days + duration of antibiotics,probiotic,probiotic formulation VSL#3,no,112,prophylactic,Development of Clostridium difficile associated diarrhoea [ Time Frame: 28 days post last antibiotic dose ],negative,participants,0,not superior,,https://pubmed.ncbi.nlm.nih.gov/23618760/,NCT00973908,Probiotics for the Prevention of Antibiotics Associated Diarrhoea and Clostridium Difficile Associated Diarrhoea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2|Phase 3,https://ClinicalTrials.gov/show/NCT00973908,,
NCT01295918-1,sustained,100000000,700000000,100000000,CFU,QD,7,7 days + duration of antibiotics,probiotic,probiotic supplement containing 1 x 10 8 CFU Lactobacillus reuteri DSM 17938 in the form of one chewable tablet once per da,no,49,prophylactic,To assess if the probiotic L. reuteri is effective in preventing AAD in children [ Time Frame: 2 years ],positive,participants,48,not superior,"The incidence of diarrhoea (defined as at least 3 loose or watery stools per day in a 48-hour period that occurred during or up to 21 days after cessation of antibiotic treatment) was unexpectedly low in both groups - L. reuteri (n=1) versus placebo (n=1): 2,04 vs. 2,1 per 100 (p>0,05, risk ratio 1,02, 95% CI 0,7-1,4).",http://www.journal-imab-bg.org/issues-2015/issue4/vol21issue4p895-900.html,NCT01295918,Probiotic Lactobacillus Reuteri to Prevent Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children,All,"Child, Adult","3 Years to 18 Years Â (Child, Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01295918,,"Lactobacillus reuteri, LMG P-27481"
NCT02589847-1,acute,,,,,,,given as quantity of enema,probiotic,RBX2660,no,142,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,112,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,,
NCT02589847-3,sustained,,,,,,,given as quantity of enema,probiotic,RBX2660,no,142,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,112,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,,
NCT02299570-1,sustained,,,2,enema,,,separated by 7 days,probiotic,RBX2660,yes,45,therapeutic,"The primary endpoint is to evaluate treatment success, defined as the absence of CDAD without the need for retreatment with C. difficile anti-infective therapy or fecal transplant (FT) at 56 days after administration of the last assigned study enema, of Group A (two enemas of RBX2660) vs. Group B (two enemas of placebo).",positive,participants,25,,,x,NCT02299570,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02299570,,
NCT02299570-3,sustained,,,1,enema,,,,probiotic,RBX2660,yes,44,therapeutic,"The primary endpoint is to evaluate treatment success, defined as the absence of CDAD without the need for retreatment with C. difficile anti-infective therapy or fecal transplant (FT) at 56 days after administration of the last assigned study enema, of Group A (two enemas of RBX2660) vs. Group B (two enemas of placebo).",positive,participants,25,,,x,NCT02299570,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02299570,,
NCT01925417-1,sustained,,,,,,,,probiotic,RBX2660,no,31,therapeutic,Number of participants who were determined to be free of CDAD at Day 56 after receiving their last dose of RBX2660.,positive,participants,27,,,x,NCT01925417,Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01925417,,
NCT02981316-2,sustained,8,32,4,capsules,BID,4,,probiotic,RBX7455,yes,10,therapeutic,absence of rCDI at 8 weeks following completion of the final treatment,positive,participants,9,,,https://pubmed.ncbi.nlm.nih.gov/32966574/,NCT02981316,Treatment of Recurrent Clostridium Difficile Infection With RBX7455,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 1,https://ClinicalTrials.gov/show/NCT02981316,,
NCT02981316-3,sustained,8,16,4,capsules,BID,2,,probiotic,RBX7455,yes,10,therapeutic,absence of rCDI at 8 weeks following completion of the final treatment,positive,participants,8,,,https://pubmed.ncbi.nlm.nih.gov/32966574/,NCT02981316,Treatment of Recurrent Clostridium Difficile Infection With RBX7455,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 1,https://ClinicalTrials.gov/show/NCT02981316,,
NCT02981316-4,sustained,4,8,2,capsules,BID,2,,probiotic,RBX7455,yes,10,therapeutic,absence of rCDI at 8 weeks following completion of the final treatment,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/32966574/,NCT02981316,Treatment of Recurrent Clostridium Difficile Infection With RBX7455,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 1,https://ClinicalTrials.gov/show/NCT02981316,,
NCT02092935-1,acute,400,4000,200,mg,BID,10,,antibiotic,ridinilazole ,no,36,therapeutic,Clinical response at test of cure,positive,participants,28,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,"SMT19969 [2,2'-bis(4-pyridyl)3H,3'-H 5,5-bibenzimidazole];SMT19969",
NCT02092935-3,sustained,400,4000,200,mg,BID,10,,antibiotic,ridinilazole ,no,28,therapeutic,Sustained clinical response,positive,participants,24,superior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,"SMT19969 [2,2'-bis(4-pyridyl)3H,3'-H 5,5-bibenzimidazole];SMT19969",
NCT02784002-2,sustained,400,4000,200,mg,BID,10,,antibiotic,ridinilazole ,no,14,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,7,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,"SMT19969 [2,2'-bis(4-pyridyl)3H,3'-H 5,5-bibenzimidazole];SMT19969",
NCT01670149-1,sustained,1200,25200,400,mg,TID,14,followed by 200mg TID for 14 days,antibiotic,Rifaximin,no,69,prophylactic,Difference in % relapse between Rifaximin and placebo at 12 weeks [ Time Frame: 12 weeks ],negative,participants,11,superior,"a difference between groups of −13.7% (95% CI −28.1% to 0.7%, p=0.06). The risk ratio was 0.54 (95% CI 0.28 to 1.05, p=0.07",https://gut.bmj.com/content/66/Suppl_2/A150.1,NCT01670149,Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01670149,rifaximin,
NCT00269399-1,acute,1200,12000,400,mg,TID,10,400 mg TID,antibiotic,rifaximin,no,117,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,67,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,rifaximin,
NCT00269399-3,sustained,1200,12000,400,mg,TID,10,400 mg TID,antibiotic,rifaximin,no,67,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,61,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,rifaximin,
NCT02437487-1,acute,,,1,108 SporQ,,,,probiotic,SER-109,no,59,therapeutic,Number of Subjects With CDI Recurrence (8 weeks after),negative,participants,26,superior,"relative risk, 2-sided 95% CI",https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa387/5817059,NCT02437487,SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02437487,,
NCT02437487-3,sustained,,,1,108 SporQ,,,,probiotic,SER-109,no,59,therapeutic,Number of Subjects With CDI Recurrence (8 weeks after),negative,participants,26,superior,"relative risk, 2-sided 95% CI",https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa387/5817059,NCT02437487,SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02437487,,
NCT02148601-2,sustained,,,,,,,,antibiotic,Standard Antibiotic Therapy,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,5,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,,vancomycin;vancomycin + metronidazole;metronidazole
NCT02589847-2,acute,,,,,,,,antibiotic,Standard of Care Antibiotics,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,23,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,,vancomycin;vancomycin + metronidazole;metronidazole
NCT02589847-4,sustained,,,,,,,,antibiotic,Standard of Care Antibiotics,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,23,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,,vancomycin;vancomycin + metronidazole;metronidazole
NCT01597505-1,acute,500,5000,250,mg,BID,10,,antibiotic,Surotomycin,no,290,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,79.0 (73.9 to 83.2),Non-Inferiority,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,"CB-183,315;surotomycin",
NCT01597505-3,sustained,500,5000,250,mg,BID,10,,antibiotic,Surotomycin,no,290,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,60.6 (55.0 to 66.0),not superior,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,"CB-183,315;surotomycin",
NCT01598311-1,acute,500,5000,250,mg,BID,10,,antibiotic,Surotomycin,no,285,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,83.4 (78.7 to 87.2),Non-Inferiority,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,"CB-183,315;surotomycin",
NCT01598311-3,sustained,500,5000,250,mg,BID,10,,antibiotic,Surotomycin,no,285,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,63.3 (57.7 to 68.7),not superior,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,"CB-183,315;surotomycin",
NCT02563106-1,sustained,600,4800,150,mg,QID,8,3 days + at least 5 days of antibiotics duration,other,SYN-004,no,206,prophylactic,Percentage of Patients With Clostridium Difficile Infection at 4- Weeks of Follow-up.,negative,participants,2,relative risk reduction,"(risk reduction 2·4%, 95% CI -0·6 to 5·9; one-sided p=0·045)",x,NCT02563106,A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI,All,"Adult, Older Adult","50 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02563106,,
NCT00196794-1,acute,9,135,3,g,TID,14,3g + 9g loading dose,antibiotic,Tolevamer potassium-sodium (GT267-004),no,268,therapeutic,Resolution of diarrhea,positive,Percentage of participants,41.8,,,https://pubmed.ncbi.nlm.nih.gov/24799326/,NCT00196794,A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00196794,GT160-246,
NCT00196794-7,sustained,9,135,3,g,TID,14,3g + 9g loading dose,antibiotic,Tolevamer potassium-sodium (GT267-004),no,105,therapeutic,Recurrence rate,negative,Percentage of participants,5.7,,,https://pubmed.ncbi.nlm.nih.gov/24799326/,NCT00196794,A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00196794,GT160-246,
NCT00106509-1,acute,9,135,3,g,TID,14,3g + 9g loading dose,antibiotic,Tolevamer potassium-sodium (GT267-004),no,266,therapeutic,Resolution of diarrhea,positive,Percentage of participants,46.6,,,https://pubmed.ncbi.nlm.nih.gov/24799326/,NCT00106509,A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00106509,GT160-246,
NCT00106509-7,sustained,9,135,3,g,TID,14,3g + 9g loading dose,antibiotic,Tolevamer potassium-sodium (GT267-004),no,117,therapeutic,Recurrence rate,negative,Percentage of participants,3.4,,,https://pubmed.ncbi.nlm.nih.gov/24799326/,NCT00106509,A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00106509,GT160-246,
NCT02423967-1,sustained,,,,,,,,FMT,Transplant uses fresh familial stool,no,2,therapeutic,Clostridium difficile (CD) Eradication; percentage of patients with negative CD toxin in stool following Fecal Microbiota Transplant [ Time Frame: 4 weeks ],positive,participants,1,,,"https://journals.lww.com/jpgn/Fulltext/2016/10002/World_Congress_of_Pediatric_Gastroenterology,.1.aspx",NCT02423967,Fresh Versus Frozen Stool for Fecal Transplant in Children,All,"Child, Adult","1 Year to 18 Years Â (Child, Adult)",Phase 1,https://ClinicalTrials.gov/show/NCT02423967,,FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates
NCT02423967-2,sustained,,,,,,,,FMT,Transplant uses frozen anonymous stool,no,6,therapeutic,Clostridium difficile (CD) Eradication; percentage of patients with negative CD toxin in stool following Fecal Microbiota Transplant [ Time Frame: 4 weeks ],positive,participants,6,non-inferior,,"https://journals.lww.com/jpgn/Fulltext/2016/10002/World_Congress_of_Pediatric_Gastroenterology,.1.aspx",NCT02423967,Fresh Versus Frozen Stool for Fecal Transplant in Children,All,"Child, Adult","1 Year to 18 Years Â (Child, Adult)",Phase 1,https://ClinicalTrials.gov/show/NCT02423967,,FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates
NCT01983683-2,acute,500,5000,125,mg,QID,10,,antibiotic,Vancomycin,no,301,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.7 (81.3 to 89.2) ,,Wilson's score method,x,NCT01983683,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01983683,vancomycin,
NCT01983683-4,sustained,500,5000,125,mg,QID,10,,antibiotic,Vancomycin,no,301,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,61.8 (56.2 to 67.1),Inferiority,Wilson's score method,x,NCT01983683,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01983683,vancomycin,
NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,Vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,vancomycin,
NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,Vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,vancomycin,
NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,Vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,vancomycin,
NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,Vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,vancomycin,
NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,Vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,83.6 (78.8 to 87.4),,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,vancomycin,
NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,Vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,61.4 (55.9 to 66.8)  ,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,vancomycin,
NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,Vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,82.1 (77.2 to 85.9),,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,vancomycin,
NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,Vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,59.0 (53.4 to 64.5),,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,vancomycin,
NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,Vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,vancomycin,
NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,Vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,vancomycin,
NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,Vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,vancomycin,
NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,Vancomycin,no,16,therapeutic,"initially cured, then relapsed",negative,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,vancomycin,
NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,Vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,vancomycin,
NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,Vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,vancomycin,
NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,vancomycin,
NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,vancomycin,
NCT00468728-1,acute,500,5000,125,mg,QID,10,,antibiotic,Vancomycin,no,256,therapeutic,Cure Rate at End of Therapy [ Time Frame: Study day 10 (+/- 2 days) ],positive,Percentage of participants,86.7 (82.0 to 90.4),,"H0: C(OPT-80) - C(VAN) <= -10% Power calculation is based on cure rate of 85% in both treatment groups, non-inferiority margin of 10%, 2.5% (1-sided) type I error rate with approximately 90% power gives a total of 530 subjects.",x,NCT00468728,PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Child, Adult, Older Adult","16 Years and older Â (Child, Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00468728,vancomycin,
NCT00468728-3,sustained,500,5000,125,mg,QID,10,,antibiotic,Vancomycin,no,222,therapeutic,Recurrence [ Time Frame: Study days 11-40 ],negative,Percentage of participants,22,,Chi-squared,x,NCT00468728,PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Child, Adult, Older Adult","16 Years and older Â (Child, Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00468728,vancomycin,
NCT00314951-1,acute,500,5000,125,mg,QID,10,,antibiotic,Vancomycin,no,307,therapeutic,Cure Rate at End of Therapy [ Time Frame: Study day 10 (+/- 2 days) ],positive,Percentage of participants,85.7 (81.3 to 89.2),,"H0: C(fidaxomicin) - C(Vancomycin) <= -10% Power calculation is based on cure rate of 85% in both treatment groups, non-inferiority margin of 10%, 2.5% (1-sided) type I error rate with approximately 90% power gives a total of 530 subjects.",x,NCT00314951,Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018),All,"Child, Adult, Older Adult","16 Years and older Â (Child, Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00314951,vancomycin,
NCT00314951-3,sustained,500,5000,125,mg,QID,10,,antibiotic,Vancomycin,no,263,therapeutic,Recurrence [ Time Frame: Study days 11-40 ],negative,Percentage of participants,25.1,,Chi-squared,x,NCT00314951,Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018),All,"Child, Adult, Older Adult","16 Years and older Â (Child, Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00314951,vancomycin,
NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,73,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,vancomycin,
NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,63,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,vancomycin,
NCT00196794-5,acute,500,5000,125,mg,QID,10,,antibiotic,Vancomycin,no,125,therapeutic,Resolution of diarrhea,positive,Percentage of participants,80.8,,,https://pubmed.ncbi.nlm.nih.gov/24799326/,NCT00196794,A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00196794,vancomycin,
NCT00196794-11,sustained,500,5000,125,mg,QID,10,,antibiotic,Vancomycin,no,102,therapeutic,Recurrence rate,negative,Percentage of participants,17.6,,,https://pubmed.ncbi.nlm.nih.gov/24799326/,NCT00196794,A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00196794,vancomycin,
NCT00106509-5,acute,500,5000,125,mg,QID,10,,antibiotic,Vancomycin,no,134,therapeutic,Resolution of diarrhea,positive,Percentage of participants,81.3,,,https://pubmed.ncbi.nlm.nih.gov/24799326/,NCT00106509,A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00106509,vancomycin,
NCT00106509-11,sustained,500,5000,125,mg,QID,10,,antibiotic,Vancomycin,no,107,therapeutic,Recurrence rate,negative,Percentage of participants,23.4,,,https://pubmed.ncbi.nlm.nih.gov/24799326/,NCT00106509,A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00106509,vancomycin,
NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin ,no,33,therapeutic,Clinical response at test of cure,positive,participants,23,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,vancomycin,
NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin ,no,23,therapeutic,Sustained clinical response,positive,participants,14,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,vancomycin,
NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,Vancomycin 125mg by mouth every 6 hours for 10 days,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,vancomycin,
NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,Vancomycin 125mg by mouth every 6 hours for 10 days,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,vancomycin,
NCT01259726-4,sustained,10000,70000,10000,spores,QD,7,,probiotic,VP20621,yes,41,therapeutic,Number of Participants With Clostridium Difficile Infection (CDI) Recurrence,negative,participants,6,superior,Treatment comparison with placebo using two-sided Chi-Square test at significance level p=0.05.,x,NCT01259726,Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01259726,"M3, a NTCD strain","Z31, a NTCD strain;NTCD-035;PCD130 + 027;PCD182 + 027;Strain 630;Clostridium difficile CD37;T7, a NTCD strain"
NCT01259726-7,sustained,10000000,70000000,10000000,spores,QD,7,,probiotic,VP20621,yes,43,therapeutic,Number of Participants With Clostridium Difficile Infection (CDI) Recurrence,negative,participants,2,superior,Treatment comparison with placebo using two-sided Chi-Square test at significance level p=0.05.,x,NCT01259726,Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01259726,"M3, a NTCD strain","Z31, a NTCD strain;NTCD-035;PCD130 + 027;PCD182 + 027;Strain 630;Clostridium difficile CD37;T7, a NTCD strain"
NCT01259726-10,sustained,10000000,140000000,10000000,spores,QD,14,,probiotic,VP20621,yes,41,therapeutic,Number of Participants With Clostridium Difficile Infection (CDI) Recurrence,negative,participants,6,superior,Treatment comparison with placebo using two-sided Chi-Square test at significance level p=0.05.,x,NCT01259726,Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01259726,"M3, a NTCD strain","Z31, a NTCD strain;NTCD-035;PCD130 + 027;PCD182 + 027;Strain 630;Clostridium difficile CD37;T7, a NTCD strain"
